Linden Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Linden Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-94,198	Closed	-$704K	–	55
2014 Q3	$704K	Sell	94,198 -89,638	-49%	-$832K	0.14%	44
2014 Q2	$1.78M	Buy	183,836 +62,027	+51%	+$553K	0.39%	37
2014 Q1	$1.01M	Buy	+121,809	New	+$1.04M	0.26%	37

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Linden Advisors's PDLI Position: Q4 2014 in Review

Linden Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2014, closing a stake of 94,198 shares — an estimated $704K sold.

Linden Advisors first reported a position in PDLI in Q1 2014 and held it in 3 quarters. The position peaked at $1.78M in Q2 2014. 223 funds tracked by Wall St. Rank hold PDLI as of Q4 2014.

Linden Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2014 after selling out during the quarter.
Linden Advisors sold 94,198 PDL BioPharma, Inc. shares in Q4 2014, an estimated $704K.
Linden Advisors first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 3 quarters.
Linden Advisors's PDL BioPharma, Inc. position peaked at $1.78M in Q2 2014.
223 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2014.

Based on Linden Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.